Skip to content

Ocular Therapeutix OCUL Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.8M+24.8%
Bausch + Lomb logo
Bausch + LombBLCO
$38M+18.8%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$0-100%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.66M+6.5%
PBH
Prestige Consumer HealthcarePBH
$6.91M+14.3%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$628K+38.3%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's operating lease liabilities (current)?
Ocular Therapeutix (OCUL) reported operating lease liabilities (current) of $3.17M in Q1 2026.
How has Ocular Therapeutix's operating lease liabilities (current) changed year-over-year?
Ocular Therapeutix's operating lease liabilities (current) increased by 47.0% year-over-year, from $2.16M to $3.17M.
What is the long-term trend for Ocular Therapeutix's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Ocular Therapeutix's operating lease liabilities (current) has grown at a 15.7% compound annual growth rate (CAGR), from $1.36M to $2.82M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.